Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Clinical trial NCT05225259 · NO_LONGER_AVAILABLE
Trial details
- NCT number
- NCT05225259
- Sponsor
- Eli Lilly and Company
- Status
- NO_LONGER_AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.